Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.

Edwards SM, Evans DG, Hope Q, Norman AR, Barbachano Y, Bullock S, Kote-Jarai Z, Meitz J, Falconer A, Osin P, Fisher C, Guy M, Jhavar SG, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Forrest MS, Dearnaley DP, Ardern-Jones AT, Page EC, Easton DF, Eeles RA; UK Genetic Prostate Cancer Study Collaborators and BAUS Section of Oncology..

Br J Cancer. 2010 Sep 7;103(6):918-24. doi: 10.1038/sj.bjc.6605822. Epub 2010 Aug 24.

2.

Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations.

Maier C, Herkommer K, Luedeke M, Rinckleb A, Schrader M, Vogel W.

Prostate. 2014 Oct;74(14):1444-51. doi: 10.1002/pros.22860. Epub 2014 Aug 11.

PMID:
25111659
3.

BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.

Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N, Guy M, Edwards S, O'Brien L, Sawyer E, Hall A, Wilkinson R, Dadaev T, Goh C, Easton D; UKGPCS Collaborators., Goldgar D, Eeles R.

Br J Cancer. 2011 Oct 11;105(8):1230-4. doi: 10.1038/bjc.2011.383. Epub 2011 Sep 27.

4.

The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.

Maia S, Cardoso M, Paulo P, Pinheiro M, Pinto P, Santos C, Pinto C, Peixoto A, Henrique R, Teixeira MR.

Fam Cancer. 2016 Jan;15(1):111-21. doi: 10.1007/s10689-015-9832-x.

PMID:
26289772
5.

High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers.

Castro E, Jugurnauth-Little S, Karlsson Q, Al-Shahrour F, Piñeiro-Yañez E, Van de Poll F, Leongamornlert D, Dadaev T, Govindasami K, Guy M, Eeles R, Kote-Jarai Z; UKGPCS, EMBRACE and IMPACT studies..

Ann Oncol. 2015 Nov;26(11):2293-300. doi: 10.1093/annonc/mdv356. Epub 2015 Sep 7.

PMID:
26347108
6.

Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.

Risbridger GP, Taylor RA, Clouston D, Sliwinski A, Thorne H, Hunter S, Li J, Mitchell G, Murphy D, Frydenberg M, Pook D, Pedersen J, Toivanen R, Wang H, Papargiris M, Lawrence MG, Bolton DM.

Eur Urol. 2015 Mar;67(3):496-503. doi: 10.1016/j.eururo.2014.08.007. Epub 2014 Aug 22.

PMID:
25154392
7.

Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.

Mitra A, Fisher C, Foster CS, Jameson C, Barbachanno Y, Bartlett J, Bancroft E, Doherty R, Kote-Jarai Z, Peock S, Easton D; IMPACT and EMBRACE Collaborators., Eeles R.

Br J Cancer. 2008 Jan 29;98(2):502-7. doi: 10.1038/sj.bjc.6604132. Epub 2008 Jan 8.

8.

Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation.

Willems AJ, Dawson SJ, Samaratunga H, De Luca A, Antill YC, Hopper JL, Thorne HJ; kConFab Investigators..

Clin Cancer Res. 2008 May 15;14(10):2953-61. doi: 10.1158/1078-0432.CCR-07-5237. Epub 2008 Apr 29.

9.

Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia.

Budroni M, Cesaraccio R, Coviello V, Sechi O, Pirino D, Cossu A, Tanda F, Pisano M, Palomba G, Palmieri G.

BMC Cancer. 2009 Feb 20;9:62. doi: 10.1186/1471-2407-9-62.

10.

High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.

Willems-Jones A, Kavanagh L, Clouston D, Bolton D; kConFab Investigators., Fox S, Thorne H.

BJU Int. 2012 Dec;110(11 Pt C):E1181-6. doi: 10.1111/j.1464-410X.2012.11519.x. Epub 2012 Oct 4.

11.

Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.

Kote-Jarai Z, Mikropoulos C, Leongamornlert DA, Dadaev T, Tymrakiewicz M, Saunders EJ, Jones M, Jugurnauth-Little S, Govindasami K, Guy M, Hamdy FC, Donovan JL, Neal DE, Lane JA, Dearnaley D, Wilkinson RA, Sawyer EJ, Morgan A, Antoniou AC, Eeles RA; UK Genetic Prostate Cancer Study Collaborators, and ProtecT Study Group..

Ann Oncol. 2015 Apr;26(4):756-61. doi: 10.1093/annonc/mdv004. Epub 2015 Jan 16.

PMID:
25595936
12.

Prostate cancer progression and survival in BRCA2 mutation carriers.

Tryggvadóttir L, Vidarsdóttir L, Thorgeirsson T, Jonasson JG, Olafsdóttir EJ, Olafsdóttir GH, Rafnar T, Thorlacius S, Jonsson E, Eyfjord JE, Tulinius H.

J Natl Cancer Inst. 2007 Jun 20;99(12):929-35. Epub 2007 Jun 12.

PMID:
17565157
13.

BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.

Ottini L, Masala G, D'Amico C, Mancini B, Saieva C, Aceto G, Gestri D, Vezzosi V, Falchetti M, De Marco M, Paglierani M, Cama A, Bianchi S, Mariani-Costantini R, Palli D.

Cancer Res. 2003 Jan 15;63(2):342-7.

14.

Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers.

Mitra AV, Jameson C, Barbachano Y, Sodha N, Kote-Jarai Z, Javed A, Bancroft E, Fletcher A, Cooper C, Peock S; IMPACT and EMBRACE Collaborators., Easton D, Eeles R, Foster CS.

Oncol Rep. 2010 Feb;23(2):299-305.

PMID:
20043088
15.

Germline BRCA1 mutations increase prostate cancer risk.

Leongamornlert D, Mahmud N, Tymrakiewicz M, Saunders E, Dadaev T, Castro E, Goh C, Govindasami K, Guy M, O'Brien L, Sawyer E, Hall A, Wilkinson R, Easton D; UKGPCS Collaborators., Goldgar D, Eeles R, Kote-Jarai Z.

Br J Cancer. 2012 May 8;106(10):1697-701. doi: 10.1038/bjc.2012.146.

16.

The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.

Vazina A, Baniel J, Yaacobi Y, Shtriker A, Engelstein D, Leibovitz I, Zehavi M, Sidi AA, Ramon Y, Tischler T, Livne PM, Friedman E.

Br J Cancer. 2000 Aug;83(4):463-6.

17.

Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer.

Agalliu I, Karlins E, Kwon EM, Iwasaki LM, Diamond A, Ostrander EA, Stanford JL.

Br J Cancer. 2007 Sep 17;97(6):826-31. Epub 2007 Aug 14.

18.

Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.

Saunders EJ, Dadaev T, Leongamornlert DA, Al Olama AA, Benlloch S, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pasayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Teixeira MR, Pandha H, Govindasami K, Muir K; UK Genetic Prostate Cancer Study Collaborators.; UK ProtecT Study Collaborators.; PRACTICAL Consortium., Easton DF, Eeles RA, Kote-Jarai Z.

Br J Cancer. 2016 Apr 12;114(8):945-52.

19.

Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene.

Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, Jackson R, Southgate C, Singh R, Falconer A, Dearnaley DP, Ardern-Jones A, Murkin A, Dowe A, Kelly J, Williams S, Oram R, Stevens M, Teare DM, Ponder BA, Gayther SA, Easton DF, Eeles RA; Cancer Research UK/Bristish Prostate Group UK Familial Prostate Cancer Study Collaborators.; British Association of Urological Surgeons Section of Oncology..

Am J Hum Genet. 2003 Jan;72(1):1-12. Epub 2002 Dec 9.

20.

Identification of germline MLH1 alterations in familial prostate cancer.

Fredriksson H, Ikonen T, Autio V, Matikainen MP, Helin HJ, Tammela TL, Koivisto PA, Schleutker J.

Eur J Cancer. 2006 Nov;42(16):2802-6. Epub 2006 Sep 11.

PMID:
16963262

Supplemental Content

Support Center